A venture capital firm and investment bank based in Las Vegas, Nevada, makes investments from its own capital and typically has a two-pronged approach in making investments while also providing guidance in the structure and development of the company. The firm looks at a broad range of sectors, including life science and healthcare with a particular interest in consumer products for direct investing. The firm typically leads investments and invests $100K to a couple million per company. The firm invests on a global level, and seeks companies based all over the world.

The firm is indication agnostic and open to opportunities in healthcare IT, diagnostics, medical devices of all classes, and laboratory equipment and drug development enabling technology. The firm is particularly interested in technology involving software, though is not as open to biotech therapeutics because of the longer time line to commercialization. The firm is typically interested in later stage companies that are generating revenue, though would be open to looking at opportunities at all stages.

The firm will typically provide guidance and leadership support after an investment, and would support the company with future endeavors, including joint ventures and licensing partnerships. The firm would take a board seat after an investment, and would help fill the management team if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm based in Northern California makes seed and venture round investments in the form of equity or convertible loans. Investments may range up to $500,000, with the potential for follow-on investments. The firm prefers to support companies based in Northern California or with ties to the region, and plans to make approximately 2 further investments.

The firm is seeking to invest in products that can be used by hospitals or health systems to solve major problems. The firm invests in medical technology, healthcare IT and also has some interest in diagnostics. In the medical device sector, the firm invests in projects at both preclinical and clinical stages of development. The firm has diverse interests and will consider investing in any area of the medical device and healthcare IT/connected device field, but possesses specialist expertise in radiology, molecular imaging/imaging devices, and electro mechanical medical devices. In addition to these areas of expertise, the fund is interested in subsectors in which the Davis/Sacramento region provides significant expertise such as regenerative medicine and telehealth. In general, the firm is interested in technologies that improve standards of care or deliver more time- or cost-efficiency for healthcare providers.

The firm works with health systems in Northern California to launch pilot projects in order to vet new technologies from the fund’s portfolio. The firm therefore focuses on opportunities that can be de-risked with this method. The firm prefers to exit investments in a short timeframe (about 2 years), and seeks a board seat in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large US-based foundation is dedicated to finding cures for blood cancer patients and invests up to $20 million of its funds per year in assets that that have the potential to change the standard of care for patients with blood cancer. The foundation invests on average $3-4 million dollars per company in a cost sharing basis, but has made investments ranging from $1.2 million-$12 million. The firm looks to provide tranched equity funding or sponsored research upon milestones for an ROI based on a mutually agreed upon definitive arrangement. The firm makes investments in innovative assets in Proof-of-Concept in patient stage of development and is looking to make 3-5 investments per year. The foundation invests globally, and will invest alone or as part of a syndicate with other investors.

The foundation is looking to invest in companies developing either a therapeutic, device or a diagnostic or supportive care product that will benefit patients with blood cancer with urgent unmet medical needs and will consider any sub sector. The foundation’s target stage however is in companies that are just beginning to obtain proof of concept data in patients; however the firm has invested in companies that have products in stages of development including IND-enabling, phase I, phase II and phase III of clinical trials.

The foundation will consider investment in a private or public company that has capital resources of their own. The foundation looks for companies with a management team that has industry experience taking drugs through the development and the regulatory process, ability to execute on a plan and strong scientific and business leadership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage venture capital firm based in Taipei, Taiwan, specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $40 million fund that is set to close in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, healthcare internet of things (IoT), and pharmaceuticals. Within medtech, the firm is looking for early stage projects that have significant entry barrier and can address unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm with a fund size of $150 million is interested in growth and buyout investments into middle market companies located in India. The firm’s typical investment size is $5m – $10m in exchange for 35%+ equity ownership. The firm is open to leading the round or co-investing alongside other firms.

The firm is interested a wide range of healthcare related sectors – including equipment, devices, biotech, suppliers and engineering, distributors, providers and payers. The firm will not invest in orphan diseases but is opportunistic with regard to indication areas. The firm has a broad range of interests but will invest only in companies based in India generating revenues of $5m – $15m.

The firm for strong, experienced and passionate management teams when making a minority investment. Management team requirements are less stringent if it is a buyout. The firm always takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private firm based in London, UK has an exclusive focus on healthcare. The firm seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

Within the healthcare space the firm is sector and indication agnostic, but intends to focus on medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Shanghai-based merchant bank has a newly formed office in Cambridge, MA, that sources healthcare investment opportunities for China-based institutional investors. The firm is interested in both acquisitions and minority equity investments; allocations have varied from $30M to $1.5BN, but for healthcare deals the firm prefers to invest $75 million or more in a given opportunity. The firm seeks opportunities in North America and Europe.

The firm is interested in any opportunity in healthcare, but has a particular interest and expertise in medical device opportunities and healthcare service facilities. In the medical device sector, the firm is only interested in companies that have a revenue-generating product, but do not need to be profitable at this time. The firm is interested in all types of medical devices, and has expertise in orthopedics.

The firm’s primary criteria is a strong strategic fit with the firm’s China-based investors, who are seeking to bring the branding and medical expertise of North American or European medical technology companies to the Asia market. The firm is interested, but not exclusively seeking companies that are planning to expand into Asia, or to grow their existing Asia business. The firm is open to investing in companies that have revenues but not profits.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com